1 Recommendations

1.1 Nintedanib is recommended as an option for treating idiopathic pulmonary fibrosis, only if:

  • the person has a forced vital capacity (FVC) between 50% and 80% of predicted

  • the company provides nintedanib with the discount agreed in the patient access scheme and

  • treatment is stopped if disease progresses (a confirmed decline in percent predicted FVC of 10% or more) in any 12‑month period.

1.2 People whose treatment with nintedanib is not recommended in this NICE guidance, but was started within the NHS before this guidance was published, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

  • National Institute for Health and Care Excellence (NICE)